Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) (”Vicore Pharma”) on 15 May 2019.
Adoption of income statement and balance sheet for the financial year 2018 and discharge from liability
The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2018 as well as the balance sheet and consolidated balance sheet as of 31 December 2018. The members of the board of directors and the managing director were discharged from liability for the financial year 2018.
Allocation of profit or loss
The AGM resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid for 2018 and that the results of the company shall be carried forward.
Election of board members and auditors, and fees to the board of directors and auditors
The AGM resolved, in accordance with the nomination committee’s proposal, to re-elect Leif Darner, Jacob Gunterberg, Maarten Kraan, Sara Malcus, Hans Schikan and Peter Strömas members of the board of directors for the period until the end of the next annual general meeting. Leif Darner was re-elected as the chairman of the board of directors. The audit firm EY AB was re-elected auditor of the company for the period until the end of the next annual general meeting.
The AGM further resolved on directors’ fees in accordance with the nomination committee’s proposal. The AGM further resolved, in accordance with the nomination committee’s proposal, that the fee to the auditor shall be paid as per approved statement of costs.
Nomination committee for the next annual general meeting
The AGM resolved, in accordance with the nomination committee’s proposal, on principles for appointing the nomination committee. In short, the principles imply that the nomination committee should be composed of the chairman of the board of directors together with one representative of each of the three largest shareholders in terms of votes, based on ownership in the company as of 31 August 2019.
Guidelines on remuneration to group management
The AGM resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to group management. In short, the guidelines state that remuneration within Vicore Pharma shall be based on principles of performance, competitiveness and fairness and consist of fixed remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits.
Authorization to issue new shares
The AGM resolved to, in accordance with the board of directors’ proposal, authorize the board of directors, at one or several occasions, with or without deviation from the shareholders’ preferential rights and for the period up until the next annual general meeting, to increase the company’s share capital by issuing new shares. The number of shares that may be issued under the authorization may not entail a dilution effect of more than 20 per cent.
Mölndal, 15 May 2019
Vicore Pharma Holding AB (publ)
For further information, please contact:
Carl-Johan Dalsgaard, CEO, Tel: +46 70 975 98 63, email@example.com
Hans Jeppsson, CFO, Tel: +46 70 553 14 65, firstname.lastname@example.org
The information was submitted for publication, through the agency of the contact persons set out above, on 15 May 2019 at 17:30 CEST.
About Vicore Pharma Holding AB (publ)
Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.
VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”) and diffuse systemic sclerosis (“dSSc”). As a result of the acquisition of INIM Pharma AB in August 2018, the company’s pipeline expanded with a second drug development program, VP02. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which has a significant high unmet need. The acquisition of INIM Pharma meant an expansion of Vicore Pharma's operation and a clear strategy focused on developing drugs for the treatment of rare and severe lung diseases. VP01 is currently within an extended phase I study and the start of the Phase IIa study in IPF patients is expected to commence during the second half of 2019. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020.
The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm. The company´s certified adviser is Erik Penser Bank, telephone: +46 8 463 83 00, e-mail: email@example.com. For more information, see www.vicorepharma.com